Aktis Oncology
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
About Aktis Oncology
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.
Company Facts
- Headquarters
- Boston
- Founded
- 2021
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- public
- Employees
- c_00051_00100
- Funding Stage
- ipo
- Total Funding
- $331,000,000
- Last Funding Type
- series_b
- Last Funding Date
- 2024-09-30
- Website
- https://www.aktisoncology.com
Industries & Categories
Biotechnology, Health Care, Life Science, Oncology
Social Links
Canonical: https://fsome.com/organization/aktis-oncology-12711 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.